BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Avalo Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-08-23 4:34 pm Purchase | 2024-08-13 | 13G | Avalo Therapeutics, Inc. AVTX | BIOTECHNOLOGY VALUE FUND L P | 967,299 9.990% | 967,299 (New Position) | Filing |